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was suffering from mental retardation and developmental delay. 
His developmental delay was noticed at the age of 1. Additionally, 
he exhibited sleep disturbances and abnormal behavior, such as 
self-injury. He had dysmorphic features including brachycephaly 
and frontal bossing. For diagnosis of the patient, we conducted a 
conventional cytogenetic study and a microdeletion assay using 
MLPA. In the conventional chromosomal study, the karyotype 
was normal, and it was reported as 46,XY [20]. As we suspected a 
microdeletion syndrome based on his phenotype, we decided to 
perform MPLA analysis. We conducted the assay with MLPA P245-
B1 microdeletion syndromes-1 probemix (MRC-Holland, Amster-
dam, The Netherlands). Analysis of the mutation was performed 
using GeneMarker 1.70 (Softgenetics, Pennsylvania, USA), and the 
analysis was based on the relative peak values of each probe am-
plication divided by the value of the control probes. The thresh-
old values to detect deletion and amplication of the genes were 
set at 0.65 and 1.3, respectively. A microdeletion screening test re-
vealed deletions of RAI1, dynein regulatory complex subunit 3 
(DRC3), and scribble cell polarity complex component (LLGL1) 
gene loci (Fig. 1A), which were diagnostic ndings of Smith-Ma-
genis syndrome with an interstitial deletion in 17p11.2. To conrm 
SMS, we conducted MLPA using the P374-A1 probemix covering 
more loci, including COP9 signalosome subunit 3 (COPS3), RAI1, 
microRNA 33b (MIR33B), target of myb1 like 2 membrane traf-
ficking protein (TOM1L2), phosphoribosyl pyrophosphate syn-
thetase associated protein 2 (PRPSAP2), and microfibril associ-
Dear Editor,
Smith-Magenis syndrome (SMS) is characterized by mental re-
tardation and developmental delay caused by an interstitial dele-
tion of chromosome 17p11.2 or a mutation in the retinoic acid in-
duced 1 (RAI1) gene [1, 2]. Additional phenotypes include neu-
robehavioral problems, such as self-injury and attention-seeking, 
sleep disorder, and distinctive craniofacial anomalies [3]. Most 
cases of SMS are de novo; in extremely rare cases, inheritance 
from parents has been reported [4]. While the worldwide inci-
dence of SMS is estimated to be one in 15,000–25,000 people [3, 
5], reports of occurrence of SMS are relatively infrequent in Ko-
rea [6-9]. We report a Korean SMS case conrmed by multiplex li-
gation-dependent probe amplication (MLPA) analysis.
The patient was a 25-year-old Korean male, the rst child of 
non-consanguineous parents with no relevant family history of 
SMS. He visited the outpatient clinical genetics department as he 
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Fig. 1. (A) MLPA analysis (red: control, blue: patient) results reveal heterozygous deletion of DRC3, LLGL1, RAI1 gene on 17p11.2. (B) Confirm test 
covering more loci reveals heterozygous deletion of COPS3, RAI1, MIR33B, TOM1L2 gene on 17p11.2. Abbreviation: MLPA, Multiplex ligation-de-
pendent probe amplification. *The name of the Leucine-rich repeat-containing protein 48 (LRRC48) gene has been changed to DRC3; †,‡RAI1 P and 
RAI1 PRO are different sets of primers of RAI1 gene. The names are randomly added with P and PRO as the analysis software requires different 
names with matching primers.
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ated protein 4 (MFAP4). The results revealed deletion of the COPS3, 
RAI1, MIR33B, and TOM1L2 genes on 17p11.2 (Fig. 1B). The nal 
diagnosis for the patient was reported as SMS. Further cytogenetic 
studies of the parents and the sibling were not conducted, as the 
parents decided to continue treatment of the patient’s sleep disor-
der at another clinic. 
SMS exhibits distinctive phenotypes consisting of neurobehav-
ioral problems, developmental delay, and craniofacial anomalies 
[3]. However, there is a wide variety of phenotypes that overlap 
with other congenital anomalies and mental retardation-related 
disease entities. For example, SMS and Down syndrome share 
several facial phenotypes, including upward slanting palpebral 
ssures, brachycephaly, at midface, and a short and broad nose 
[10]. It can be challenging, especially in early infancy, to suspect 
SMS solely based on the symptoms and signs of patients, often 
leading to use of a conventional chromosomal study as a screen-
ing test. However, as is often the case, a microdeletion of 17p11.2 
is not detectable via conventional karyotyping and diagnostic pro-
cess can be more difcult. To compensate for the limitations of 
conventional cytogenetics, further studies such as uorescent in 
situ hybridization (FISH), MLPA, quantitative real time PCR, chro-
mosomal microarray (CMA), and targeted sequencing are needed 
[11]. 
FISH has been widely used as a rst-tier test to detect microde-
letion syndromes. The detection rate of cryptic aberrations using 
FISH is approximately 5–7% [12]. As FISH has a specic limitation, 
which is it can target only a few loci at a time, MLPA—which can 
target 40–50 loci in a single test—may be a viable alternative. De-
tection rates of causative genetic anomalies using MLPA go up to 
31.8% when combining several MLPA kits [13]. CMA has a resolu-
tion of as much as 400 kb, which is more than a 10-fold improve-
ment compared to G-banded karyotyping [14]. Owing to its clini-
cal effectiveness, CMA is now suggested as the new rst-tier screen-
ing test for patients with multiple congenital anomalies and men-
tal retardation [14, 15]. However, it can be costly for large-scale use. 
In Korea, CMA is available only for research, and it is not used for 
routine diagnostic purposes in clinical laboratories. Considering 
the large cost and unavailability of CMA, a viable alternative may 
be MLPA screening. MLPA has a short turn-around time and is easy 
to conduct; most importantly, MLPA analysis results are highly re-
liable. 
We described an SMS case with microdeletions in the chromo-
somal region 17p11.2. This is the rst MLPA-conrmed SMS case 
in Korea. We suggest the use of MLPA as the choice of screening 
method for patients with developmental delay and mental retar-
dation, in Korea.
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